NO20072290L - Organiske forbindelser. - Google Patents

Organiske forbindelser.

Info

Publication number
NO20072290L
NO20072290L NO20072290A NO20072290A NO20072290L NO 20072290 L NO20072290 L NO 20072290L NO 20072290 A NO20072290 A NO 20072290A NO 20072290 A NO20072290 A NO 20072290A NO 20072290 L NO20072290 L NO 20072290L
Authority
NO
Norway
Prior art keywords
staurosporin
benzoyl
organic compounds
warm
processes
Prior art date
Application number
NO20072290A
Other languages
English (en)
Other versions
NO338960B1 (no
Inventor
Michael Mutz
Pascale Hoehn
Bernd Koch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35501294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072290(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20072290L publication Critical patent/NO20072290L/no
Publication of NO338960B1 publication Critical patent/NO338960B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Oppfinnelsen vedrører en ny krystallinsk form II av N-benzoyl-staurosporin; sammensetninger som inneholder denne; fremgangsmåter for fremstilling derav; og anvendelse av krystallinsk form II av N-benzoyl-staurosporin i diagnostiske metoder eller terapeutisk behandling av varmblodige dyr, spesielt men-nesker. Oppfinnelsen vedrører de amorfe formene av N-benzoyl-staurosporin; sammensetninger som inneholder disse; fremgangsmåter for fremstilling derav; og anvendelse av amorft N-benzoyl-staurosporin i diagnostiske metoder eller farmasøytisk behandling av varmblodige dyr, spesielt mennesker.
NO20072290A 2004-11-05 2007-05-02 En krystallinsk form av N-benzoyl-staurosporin, fremgangsmåte for fremstilling derav, anvendelse derav for behandling av en tumorsykdom, og sammensetninger som innbefatter denne. NO338960B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62534304P 2004-11-05 2004-11-05
US64213105P 2005-01-07 2005-01-07
PCT/EP2005/011789 WO2006048296A1 (en) 2004-11-05 2005-11-03 Organic compounds

Publications (2)

Publication Number Publication Date
NO20072290L true NO20072290L (no) 2007-05-30
NO338960B1 NO338960B1 (no) 2016-11-07

Family

ID=35501294

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20072290A NO338960B1 (no) 2004-11-05 2007-05-02 En krystallinsk form av N-benzoyl-staurosporin, fremgangsmåte for fremstilling derav, anvendelse derav for behandling av en tumorsykdom, og sammensetninger som innbefatter denne.
NO20161152A NO340404B1 (no) 2004-11-05 2016-07-12 Fremgangsmåte for rensing av staurosporin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20161152A NO340404B1 (no) 2004-11-05 2016-07-12 Fremgangsmåte for rensing av staurosporin

Country Status (31)

Country Link
US (2) US8198435B2 (no)
EP (3) EP2272850B1 (no)
JP (4) JP5057986B2 (no)
KR (3) KR101333851B1 (no)
CN (2) CN102993213A (no)
AR (1) AR052322A1 (no)
AU (2) AU2005300693B2 (no)
BR (1) BRPI0517689A (no)
CA (1) CA2584911C (no)
CY (1) CY1113059T1 (no)
DK (1) DK1812448T3 (no)
EC (1) ECSP12007431A (no)
ES (1) ES2388142T3 (no)
GT (1) GT200500311A (no)
HK (1) HK1211587A1 (no)
HR (1) HRP20120652T1 (no)
IL (3) IL182691A (no)
JO (1) JO2897B1 (no)
MA (1) MA29033B1 (no)
MX (2) MX346525B (no)
MY (2) MY154878A (no)
NO (2) NO338960B1 (no)
NZ (3) NZ554653A (no)
PE (3) PE20060947A1 (no)
PL (1) PL1812448T3 (no)
PT (1) PT1812448E (no)
RU (2) RU2394038C2 (no)
SI (1) SI1812448T1 (no)
TN (1) TNSN07165A1 (no)
TW (4) TWI455941B (no)
WO (1) WO2006048296A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2454220C2 (ru) 2006-08-16 2012-06-27 Новартис Аг Способ получения твердых дисперсий высококристаллических терапевтических соединений
EP2327706A1 (en) 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
KR20160008267A (ko) 2014-07-14 2016-01-22 주식회사 윈스 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템
EP3592749A1 (en) * 2017-03-06 2020-01-15 Teva Pharmaceutical Works Ltd. Solid state forms of midostaurin
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza
WO2020261293A1 (en) * 2019-06-24 2020-12-30 Dr. Reddy's Laboratories Limited Process for preparation of midostaurin
IT201900014346A1 (it) * 2019-08-08 2021-02-08 Procos Spa Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo
IT202000004291A1 (it) 2020-03-02 2021-09-02 Indena Spa Processo per la purificazione di alcaloidi indolo carbazolici
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2023205504A1 (en) * 2022-04-22 2023-10-26 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS60185719A (ja) 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5073633A (en) * 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
US5096330A (en) * 1990-06-21 1992-03-17 M-B-W Inc. Pitch control mechanism for a surface finishing machine
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH05247955A (ja) 1992-03-06 1993-09-24 Taisei Corp 擁壁の施工方法
DE69326388T2 (de) 1992-06-22 1999-12-30 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur Herstellung von Staurosporin-Derivaten
AU2565895A (en) * 1994-06-01 1995-12-21 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
RU2191175C2 (ru) * 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
BR9917475B1 (pt) 1999-08-30 2013-07-23 processo para a manufatura de compostos, e, modificação do processo.
EP1372611B1 (en) 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
KR100407758B1 (ko) 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
US7608420B2 (en) 2003-04-22 2009-10-27 Lonza Ag Process for the recovery of staurosporine from a fermentation broth

Also Published As

Publication number Publication date
KR20120101601A (ko) 2012-09-13
HK1108881A1 (en) 2008-05-23
IL182691A0 (en) 2007-09-20
DK1812448T3 (da) 2012-08-27
US8710216B2 (en) 2014-04-29
TW201247681A (en) 2012-12-01
NO20161152A1 (no) 2007-05-30
NO340404B1 (no) 2017-04-18
PE20090433A1 (es) 2009-05-05
TNSN07165A1 (en) 2008-11-21
AR052322A1 (es) 2007-03-14
TWI530501B (zh) 2016-04-21
KR20070083979A (ko) 2007-08-24
CA2584911C (en) 2017-10-24
JP5701246B2 (ja) 2015-04-15
JP2017061578A (ja) 2017-03-30
US8198435B2 (en) 2012-06-12
AU2009245817A1 (en) 2009-12-24
WO2006048296A1 (en) 2006-05-11
IL207702A0 (en) 2010-12-30
RU2007120695A (ru) 2008-12-10
KR20120101600A (ko) 2012-09-13
TW200628474A (en) 2006-08-16
NZ554653A (en) 2010-10-29
EP2272850B1 (en) 2017-05-10
JP2015063569A (ja) 2015-04-09
TWI455941B (zh) 2014-10-11
EP2955186A1 (en) 2015-12-16
MA29033B1 (fr) 2007-11-01
BRPI0517689A (pt) 2008-10-14
EP1812448B1 (en) 2012-05-23
JP2012149099A (ja) 2012-08-09
CY1113059T1 (el) 2016-04-13
AU2009245817B2 (en) 2013-02-21
RU2009137788A (ru) 2011-04-20
PE20060947A1 (es) 2006-10-30
EP2272850A3 (en) 2011-09-21
JO2897B1 (en) 2015-09-15
US20090137552A1 (en) 2009-05-28
ECSP12007431A (es) 2012-06-29
CN102627658A (zh) 2012-08-08
GT200500311A (es) 2006-05-22
RU2394038C2 (ru) 2010-07-10
TW201247680A (en) 2012-12-01
CN102993213A (zh) 2013-03-27
NO338960B1 (no) 2016-11-07
AU2005300693B2 (en) 2010-08-19
MX346525B (es) 2017-03-23
TWI530500B (zh) 2016-04-21
EP1812448A1 (en) 2007-08-01
PE20130377A1 (es) 2013-04-03
TW201446773A (zh) 2014-12-16
IL207702A (en) 2016-09-29
MX2007005429A (es) 2007-05-18
KR101333851B1 (ko) 2013-11-27
IL217571A (en) 2017-07-31
US20120322789A1 (en) 2012-12-20
HK1211587A1 (en) 2016-05-27
TWI433852B (zh) 2014-04-11
JP5057986B2 (ja) 2012-10-24
KR101289998B1 (ko) 2013-07-30
PL1812448T3 (pl) 2012-10-31
HRP20120652T1 (hr) 2012-09-30
PT1812448E (pt) 2012-08-24
JP2008518995A (ja) 2008-06-05
SI1812448T1 (sl) 2012-09-28
CA2584911A1 (en) 2006-05-11
RU2467012C2 (ru) 2012-11-20
KR101265850B1 (ko) 2013-05-20
IL182691A (en) 2013-02-28
MY147404A (en) 2012-11-30
AU2005300693A1 (en) 2006-05-11
EP2272850A2 (en) 2011-01-12
NZ588025A (en) 2012-04-27
MY154878A (en) 2015-08-14
NZ599033A (en) 2012-09-28
ES2388142T3 (es) 2012-10-09

Similar Documents

Publication Publication Date Title
NO20072290L (no) Organiske forbindelser.
PT2275097T (pt) Composições que incluem canabinoides para tratamento de náuseas, vómitos, émese, enjoo ou condições idênticas
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
EA200900959A1 (ru) Ингибиторы мек
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2005074607A3 (en) Method of treating hemolytic disease
NO20083153L (no) Kjemiske forbindelser
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
WO2008069889A3 (en) Methods of treating hemolytic anemia
WO2008043052A3 (en) Human antibodies neutralizing human metapneumovirus
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
NO20075111L (no) Farmasoytisk sammensetning
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
WO2006047032A3 (en) Indole compounds useful as serotonin selective agents
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
NO20073631L (no) Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
NO20091771L (no) Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat